AVMA-endorsed xylazine legislation reintroduced in CongressFebruary 20, 2025The AVMA reintroduced the Combating Illicit Xylazine Act in both the House and Senate. The legislation is reported to provide the U.S. Drug Enforcement Administration (DEA) with tools to help address the illicit drug by scheduling xylazine as a Schedule III drug, ensure common veterinary uses of the drug remain legal, help maintain the availability of the drug on the market for veterinarians, and allow the DEA to track the legitimate supply.
SPONSORED CONTENTCurrent users report reduced stress for parvovirus care1Research shows that our Canine Parvovirus Monoclonal Antibody can help veterinary care teams work with less stress.1 Learn what CPMA can do for your parvo protocol. + Read More
"Doctor, I missed a heartworm dose!"November 13, 2020Temporaray pandemic-related disruption to pet wellness visits may have resulted in lapses in administering heartworm prophylaxis. What now?
VPN Plus+ ExclusivePlaying monopoly with real money: How veterinarians are losing the price warOctober 30, 2020By Patty Khuly, VMD, MBACompetition is alive and well in veterinary medicine. But as our industry confronts increased corporatization and consolidation, the word has acquired a new resonance for many of us.
VPN Plus+ ExclusiveIs immunotherapy the key to wiping out canine cancer?June 24, 2020An intact and functional immune system is essential to protect an organism against invading pathogens and infectious disease. However, the immune system also plays a pivotal role in identifying and eliminating transformed cells that, if left unchecked, would progress to cancer. Clinical evidence of the immune system's ability to control cancer comes from a number of observations in both the veterinary and medical settings. Consider the following examples: Cats receiving chronic immunosuppression following renal transplant …
VPN Plus+ ExclusiveCBD or CBD and THC combined?May 29, 2020While cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) are both phytocannabinoids derived from cannabis plants, differences in their chemical structures allow each to interact with unique receptors, resulting in distinct molecular targets and physiological effects. Namely, THC shows high affinity toward CB1 receptors, which are present in central and peripheral neurons, resulting in the euphoric effect commonly attributed to cannabis intoxication. In contrast, CBD does not bind CB1 at relevant concentrations and is nonintoxicating. Instead, CBD interacts, …
Pharma manufacturer expands with purchase of facility in FranceApril 3, 2020A U.S.-based manufacturer of canine and equine joint health pharmaceuticals has expanded its capabilities with the purchase of a European active pharmaceutical ingredient (API) manufacturing plant.
Getting a handle on your controlled substances costsJanuary 3, 2020Maintaining your controlled substances can be difficult and frustrating, but it doesn’t have to be if you train your staff and implement the proper protocols.
Global associations commit to improving access to veterinary medicinesOctober 21, 2019Securing equal access to vital veterinary medicines for companion animal veterinarians around the world is at the center of a new campaign spearheaded by World Small Animal Veterinary Association (WSAVA). Restricted access to veterinary medicines is a long-standing problem and limits the efforts of many veterinarians to provide optimal care to their patients in regions such as Eastern Europe, Africa, and Asia, the association says. The problem extends to even essential medicines, such as those …
Managing gastric ulcersAugust 27, 2019In the late 1980s, a rash of publications stated horses were prone to gastric ulcers. It was a bit curious, actually. Prior to that time, gastric ulceration was essentially unknown. Then, almost suddenly, gastric ulcers were being blamed for a whole host of problems, such as colic, loss of appetite, poor performance, anxiety, poor hair coat… you name it. It was perhaps also curious that, before all the published reports, no one had really noticed …
Altaire issues voluntary recall of veterinary ophthalmic drugsAugust 26, 2019Altaire Pharmaceuticals has issued a voluntary recall of some of its veterinary ophthalmic drug products and lots over quality assurance concerns. According to the company, the products are manufactured and labeled exclusively for Dechra Veterinary Products. The recalled products are: Vetropolycin Ophthalmic Ointment NDC Number: 17033-028-38 Package Size: 3.5 gm Lot #:/ Exp. Date: 17245/RHG (08/19), 17246/RHH (08/19), 17265/RHQ (09/19), 17305/RJE (10/19), 17329/RKD (11/19), 17330/RKE (11/19), 17331/RKF (11/19), 17245/RHG (08/19), 17246/RHH (08/19), 17265/RHQ (09/19), 17305/RJE …
